Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy
Since the first genetically-engineered clinical trial was posted to clinicaltrials.gov in 2003 (NCT00019136), chimeric antigen receptor (CAR) and T-cell receptor (TCR) therapies have exhibited unprecedented growth. USA, China, and Europe have emerged as major sites of investigation as many new biote...
Main Authors: | Laetitia Pinte, Amy Cunningham, Helene Trébéden-Negre, Sarah Nikiforow, Jerome Ritz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.608485/full |
Similar Items
-
Chimeric antigen receptor T-cells for glioblastoma: The journey ahead
by: Sujith Kurian Joseph, et al.
Published: (2019-01-01) -
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
by: Rowa Y. Alhabbab
Published: (2020-04-01) -
Optimized DNA electroporation for primary human T cell engineering
by: Zhang Zhang, et al.
Published: (2018-01-01) -
Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors
by: Hiroshi Fujiwara
Published: (2014-12-01) -
The why, what, and how of the new FACT standards for immune effector cells
by: Marcela V. Maus, et al.
Published: (2017-04-01)